Well Done LLC Increases Stake in Pfizer Inc. $PFE

Well Done LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 4.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,433 shares of the biopharmaceutical company’s stock after purchasing an additional 527 shares during the period. Well Done LLC’s holdings in Pfizer were worth $301,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $28,000. Horizon Financial Services LLC acquired a new stake in Pfizer in the 1st quarter valued at $35,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer in the 1st quarter worth $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Berenberg Bank dropped their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, September 20th. Finally, Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Trading Down 0.3%

PFE opened at $24.07 on Thursday. The stock has a market capitalization of $136.82 billion, a PE ratio of 12.80, a P/E/G ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business’s 50 day moving average price is $24.59 and its 200 day moving average price is $24.18.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.